Abstracts tagged "scleroderma-like conditions"

Abstract Number: 809 • 2019 ACR/ARP Annual Meeting
TNF-α Drives Progressive Obliterative Pulmonary Vascular Disease and Represents a Novel Model of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH)
Benjamin Korman¹, Richard Bell ¹, R James White ², Maria de la luz Garcia-Hernandez ³, Emily Wu ², Pamela Slattery ², Nelson Huertas ², Stacey Duemmel ², Marc Nuzzo ², Homaira Rahimi ⁴, Craig Morrell ², Christopher Ritchlin ³ and Edward Schwarz ², ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY, ³Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ⁴University of Rochester Medical Center, Rochester
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disease characterized by an obliterative vasculopathy and vascular remodeling, right heart hypertrophy, and premature death. Connective…
Abstract Number: 1640 • 2019 ACR/ARP Annual Meeting
Cutaneous and Musculoskeletal Clinical Characterization of a Cohort of Patients with Chronic Graft-versus-host Disease
Cristina Hidalgo¹, Lucía López Corral ², Concepción Roman ², Luis Gómez-Lechón ³, Maria Elisa Acosta ⁴, Olga Compan ⁵, Estefania Pérez ², Carlos Montilla ⁴ and Maria Dolores Caballero ⁶, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³Hospital Universiatrio, Salamanca, Castilla y Leon, Spain, ⁴Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁵Hospital Clinico Universitario de Salamanca, SALAMANCA, Spain, ⁶Hispital Universitario, Salamanca, Castilla y Leon, Spain
Background/Purpose: Introduction: Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HCT). Clinically, cGVHD is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].